PMID- 37686611
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230911
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 17
DP  - 2023 Aug 30
TI  - The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on 
      Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for 
      CD19-Directed CAR T-Cell Therapy in The Netherlands.
LID - 10.3390/cancers15174334 [doi]
LID - 4334
AB  - The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for 
      patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) 
      substantially differ across countries. In the Netherlands, the CAR-T tumorboard 
      facilitates a unique nationwide infrastructure for referral, eligibility 
      assessment and data collection. The aim of this study was to evaluate real-world 
      outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including 
      the thus-far underreported effects on health-related quality of life (HR-QoL). 
      All patients with R/R LBCL after >/=2 lines of systemic therapy referred for 
      axi-cel treatment between May 2020-May 2022 were included (N = 250). Of the 160 
      apheresed patients, 145 patients received an axi-cel infusion. The main reason 
      for ineligibility was rapidly progressive disease. The outcomes are better or at 
      least comparable to other studies (best overall response rate: 84% (complete 
      response: 66%); 12-month progression-free-survival rate and overall survival 
      rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by 
      infections. Clinically meaningful improvement in several HR-QoL domains was 
      observed from Month 9 onwards. Expert-directed patient selection can support 
      effective and sustainable application of CAR-T treatment. Matched comparisons 
      between cohorts will help to understand the differences in outcomes across 
      countries and select best practices. Despite the favorable results, for a 
      considerable proportion of patients with R/R LBCL there still is an unmet medical 
      need.
FAU - Spanjaart, Anne M
AU  - Spanjaart AM
AD  - Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB 
      Amsterdam, The Netherlands.
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The 
      Netherlands.
FAU - Pennings, Elise R A
AU  - Pennings ERA
AUID- ORCID: 0000-0001-7674-2148
AD  - Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB 
      Amsterdam, The Netherlands.
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The 
      Netherlands.
AD  - Erasmus School of Health Policy and Management, Erasmus University Rotterdam, 
      3062 PA Rotterdam, The Netherlands.
FAU - Mutsaers, Pim G N J
AU  - Mutsaers PGNJ
AUID- ORCID: 0000-0002-3924-8578
AD  - Department of Hematology, Erasmus MC Cancer Institute, University Medical Center 
      Rotterdam, 3015 GD Rotterdam, The Netherlands.
FAU - van Dorp, Suzanne
AU  - van Dorp S
AD  - Department of Hematology, Radboud University Medical Center, 6500 HB Nijmegen, 
      The Netherlands.
FAU - Jak, Margot
AU  - Jak M
AUID- ORCID: 0000-0001-8092-3566
AD  - Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The 
      Netherlands.
FAU - van Doesum, Jaap A
AU  - van Doesum JA
AD  - Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, 
      The Netherlands.
FAU - de Boer, Janneke W
AU  - de Boer JW
AUID- ORCID: 0000-0002-0221-1835
AD  - Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, 
      The Netherlands.
FAU - Niezink, Anne G H
AU  - Niezink AGH
AD  - Department of Radiation Oncology, University Medical Center Groningen, 9713 GZ 
      Groningen, The Netherlands.
FAU - Kos, Milan
AU  - Kos M
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, 
      1081 HV Amsterdam, The Netherlands.
FAU - Vermaat, Joost S P
AU  - Vermaat JSP
AUID- ORCID: 0000-0002-1628-6256
AD  - Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The 
      Netherlands.
FAU - Sijs-Szabo, Aniko
AU  - Sijs-Szabo A
AD  - Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The 
      Netherlands.
FAU - van der Poel, Marjolein W M
AU  - van der Poel MWM
AD  - Department of Internal Medicine, Division of Hematology, GROW School for Oncology 
      and Developmental Biology, Maastricht University Medical Center, 6229 HX 
      Maastricht, The Netherlands.
FAU - Nijhof, Inger S
AU  - Nijhof IS
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 
      1081 HV Amsterdam, The Netherlands.
AD  - Department of Internal Medicine-Hematology, St Antonius Hospital, 3435 CM 
      Nieuwegein, The Netherlands.
FAU - Kuipers, Maria T
AU  - Kuipers MT
AUID- ORCID: 0000-0003-4327-2316
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 
      1081 HV Amsterdam, The Netherlands.
FAU - Chamuleau, Martine E D
AU  - Chamuleau MED
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 
      1081 HV Amsterdam, The Netherlands.
FAU - Lugtenburg, Pieternella J
AU  - Lugtenburg PJ
AUID- ORCID: 0000-0002-6735-8651
AD  - Department of Hematology, Erasmus MC Cancer Institute, University Medical Center 
      Rotterdam, 3015 GD Rotterdam, The Netherlands.
FAU - Doorduijn, Jeanette K
AU  - Doorduijn JK
AD  - Department of Hematology, Erasmus MC Cancer Institute, University Medical Center 
      Rotterdam, 3015 GD Rotterdam, The Netherlands.
FAU - Serroukh, Yasmina I M
AU  - Serroukh YIM
AD  - Department of Hematology, Erasmus MC Cancer Institute, University Medical Center 
      Rotterdam, 3015 GD Rotterdam, The Netherlands.
FAU - Minnema, Monique C
AU  - Minnema MC
AUID- ORCID: 0000-0002-3139-8379
AD  - Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The 
      Netherlands.
FAU - van Meerten, Tom
AU  - van Meerten T
AUID- ORCID: 0000-0002-5581-6950
AD  - Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, 
      The Netherlands.
FAU - Kersten, Marie Jose
AU  - Kersten MJ
AD  - Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB 
      Amsterdam, The Netherlands.
AD  - Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.
AD  - LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The 
      Netherlands.
CN  - Dutch CAR-T Tumorboard Consortium
LA  - eng
GR  - 875171/European Union's Horizon 2020 research and innovation program under grant 
      agreement No. 875171, QUALITOP/
GR  - 116026/Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 
      116026), T2EVOLVE. This Joint Undertaking receives support from the European 
      Union's Horizon 2020 Research and Innovation program and European Federation of 
      Pharmaceutical Industries/
PT  - Journal Article
DEP - 20230830
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10486925
OTO - NOTNLM
OT  - CAR T-cell therapy
OT  - LBCL
OT  - outcomes
OT  - real-world data
COIS- M.J. received honoraria from Kite/Gilead and BMS/Celgene, has a 
      consulting/advisory role for Janssen and received research funding from Novartis. 
      A.G.H.N. discloses conflicts of interest all outside of the submitted work with: 
      IBA, PHILIPS, MIRADA, RaySearch, Siemens, Elekta, Leonie and Genentech. 
      M.W.M.v.d.P. received honoraria from Kite/Gilead and Takeda. M.T.K. has a 
      consulting/advisory role for CellPoint. M.E.D.C. has a consulting/advisory role 
      for AbbVie and Novartis and received research funding from BMS/Celgene, Gilead 
      and GenMAb. P.J.L. received honoraria for advisory boards from Genmab, AbbVie, 
      Roche, Regeneron and Incyte, has a consulting role for Y-mAbs Therapeutics, is in 
      the speakers' bureau for Lilly and AbbVie, and has received travel support from 
      Celgene and research funding from Takeda and Servier. M.C.M. has a 
      consulting/advisory role for Janssen Cilag, CDR life, GSK and the speakers' 
      bureau for Doen, Janssen Cilag, BMS, WebMD global. T.v.M. has served on the 
      advisory boards of Kite/Gilead, Celgene/BMS, Jansen and Lilly and received 
      research funding from Kite/Gilead, Celgene/BMS, Genentech and Siemens. M.J.K. 
      received honoraria from and performed in a consulting/advisory role for 
      BMS/Celgene, Kite, a Gilead Company, Miltenyi Biotec, Novartis and Roche, as well 
      as receiving research funding from Kite, a Gilead Company, Roche, Takeda, and 
      Celgene and travel support from Kite, a Gilead Company, Miltenyi Biotec, 
      Novartis, and Roche (all to institutions). A.M.S., E.R.A.P., P.G.N.J.M., S.v.D., 
      J.A.v.D., J.W.d.B., M.K., J.S.P.V., A.S.-S., I.S.N., J.K.D. and Y.I.M.S. declare 
      no conflicts of interest.
EDAT- 2023/09/09 11:43
MHDA- 2023/09/09 11:44
PMCR- 2023/08/30
CRDT- 2023/09/09 01:15
PHST- 2023/07/03 00:00 [received]
PHST- 2023/08/01 00:00 [revised]
PHST- 2023/08/25 00:00 [accepted]
PHST- 2023/09/09 11:44 [medline]
PHST- 2023/09/09 11:43 [pubmed]
PHST- 2023/09/09 01:15 [entrez]
PHST- 2023/08/30 00:00 [pmc-release]
AID - cancers15174334 [pii]
AID - cancers-15-04334 [pii]
AID - 10.3390/cancers15174334 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334.